MedTrace Logo

Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan

NCT00602004 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2015-05-12

No results posted yet for this study

Summary

The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic kidney disease (CKD) who have an arteriovenous fistula created.

Secondary outcomes include the impact of the medication on BNP and hyperkalaemia

Conditions

  • Renal Failure
  • Left Ventricular Hypertrophy

Interventions

DRUG

losartan

losartan 50 mg a day

Sponsors & Collaborators

  • Melbourne Health

    lead OTHER

Principal Investigators

  • Anuradha Aggarwal · Melbourne Health

  • Eugenia Pedagogos, FRACP,PhD · Melbourne Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2014-08-31
Completion
2014-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00602004 on ClinicalTrials.gov